Johnson And Johnson Quick Ratio (JNJ) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Johnson and Johnson  (NYSE: JNJ)

Johnson And Johnson's Quick Ratio

JNJ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.38 below Johnson And Johnson average.

Within Major Pharmaceutical Preparations industry 393 other companies have achieved higher Quick Ratio than Johnson And Johnson in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 104 to 2650.

Explain Quick Ratio?
How much Cash & cash equivalents JNJ´s has?
What are JNJ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

JNJ Quick Ratio (Jun 28 2026)
Q2		 (Mar 29 2026)
Q1		 (Dec 28 2025)
Q4		 (Sep 28 2025)
Q3		 (Jun 29 2025)
Q2
Y / Y Current Liabilities Change 64.57 % 3.13 % 6.91 % -11.43 % -8.34 %
Y / Y Cash & cash equivalent Change 11.73 % -43.14 % -18.02 % -8.55 % -25.89 %
Quick Ratio MRQ 0.38 0.56 0.57 0.63 0.57
JNJ's Total Ranking # 2650 # 104 # 1065 # 1944 # 1905
Seq. Current Liabilities Change 39.62 % 12.33 % 18.6 % -11.52 % -12.5 %
Seq. Cash & cash equivalent Change -4.34 % 9.7 % 8.3 % -1.68 % -51.32 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 394
Healthcare Sector # 749
Overall Market # 2650


Quick Ratio Statistics
High Average Low
2.62 0.98 0.21
(Jul 03 2016)   (Dec. 30. 2006)




Financial Statements
Johnson And Johnson's Current Liabilities $ 54,895 Millions Visit JNJ's Balance sheet
Johnson And Johnson's Cash & cash equivalent $ 21,094 Millions Visit JNJ's Balance sheet
Source of JNJ's Sales Visit JNJ's Sales by Geography


Cumulative Johnson And Johnson's Quick Ratio

JNJ's Quick Ratio for the trailling 12 Months

JNJ Quick Ratio

 (Jun 28 2026)
12 Months		 (Mar 29 2026)
12 Months		 (Dec 28 2025)
12 Months		 (Sep 28 2025)
12 Months		 (Jun 29 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.4 % -2.41 % 0.74 % 0.9 % 7.64 %
Y / Y Cash & cash equivalent TTM Growth -20.17 % -27.03 % -0.19 % 6.14 % 4.43 %
Quick Ratio TTM 0.52 0.58 0.71 0.75 0.75
Total Ranking TTM # 4085 # 3948 # 2510 # 3274 # 3164
Seq. Current Liabilities TTM Growth 15.7 % 0.88 % 1.69 % -2.77 % -2.16 %
Seq. Cash & cash equivalent TTM Growth 2.78 % -17.37 % -4.39 % -1.69 % -6.05 %

Quick ratio ranking by company, industry and sector >> Back to JNJ Financial Strength Comparisons >> Go to Compare JNJ Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $54,895.00 millions, cumulative Quick Ratio decreased to 0.52 below the Johnson And Johnson average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Johnson And Johnson. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3948 to 4085.

Explain Quick Ratio?
How much Cash & cash equivalents JNJ´s has?
What are JNJ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 906
Within the Market # 4085


trailing twelve months Quick Ratio Statistics
High Average Low
1.77 0.82 0.31
(Jan 01 2017)   (Sep. 30, 2007)




Companies with similar Quick Ratio in the quarter ending Jun 28 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 28 2026 MRQ Cash & cash equivalentJun 28 2026 MRQ Current Liabilities
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions
Geron Corporation  0.92 $ 64.781  Millions$ 70.331  Millions
Zomedica Corp   0.84 $ 7.605  Millions$ 9.002  Millions
Cocrystal Pharma Inc   0.83 $ 2.169  Millions$ 2.616  Millions
Harrow Inc   0.82 $ 83.889  Millions$ 102.171  Millions
Cue Biopharma Inc   0.82 $ 17.414  Millions$ 21.218  Millions
Zoetis Inc   0.81 $ 1,676.000  Millions$ 2,061.000  Millions
Organogenesis Holdings Inc   0.81 $ 46.097  Millions$ 56.963  Millions
Bridgebio Pharma Inc   0.81 $ 720.160  Millions$ 890.648  Millions
Nrx Pharmaceuticals Inc   0.79 $ 26.686  Millions$ 33.874  Millions
Oncolytics Biotech Inc   0.79 $ 4.115  Millions$ 5.225  Millions
Moleculin Biotech Inc   0.78 $ 7.262  Millions$ 9.313  Millions
Seres Therapeutics Inc   0.78 $ 15.594  Millions$ 20.031  Millions
Travere Therapeutics Inc   0.77 $ 117.735  Millions$ 152.025  Millions
Arcus Biosciences Inc   0.77 $ 153.000  Millions$ 198.000  Millions
Alkermes Plc   0.77 $ 511.529  Millions$ 662.091  Millions
Integrated Biopharma Inc  0.77 $ 4.471  Millions$ 5.802  Millions
Cyclerion Therapeutics Inc   0.75 $ 1.391  Millions$ 1.843  Millions
Dar Bioscience Inc   0.75 $ 12.618  Millions$ 16.923  Millions
Heron Therapeutics Inc   0.70 $ 64.643  Millions$ 92.145  Millions
Amphastar Pharmaceuticals Inc   0.70 $ 331.903  Millions$ 476.848  Millions
Axsome Therapeutics Inc   0.69 $ 319.850  Millions$ 460.446  Millions

Date modified: 2026-09-26T07:18:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.